India flu diagnostic and treatment market is projected to grow at a CAGR of 11.71% throughout the forecast period. The flu diagnostic and treatment market in India is poised to surge at a notable CAGR on account of the rapidly rising incidence of influenza throughout the country. Furthermore, the growing investments in the field of influenza treatment especially among the high-risk population which primarily include pregnant women, infants, and the aged population are some of the key factors bolstering the flu diagnostic and treatment market growth in the country during the next five years. Furthermore, the market in India is also projected to grow at a significant rate due to the lack of proper vaccination policy particularly focusing on influenza which is anticipated to drive the demand for flu diagnostic and treatment solutions in the coming years. Apart from Mission Indradhanush, the country does not have any seasonal influenza vaccination/immunization policy.
However, the market growth for flu diagnostic and treatment in India may be restrained by the fact that there is a large proportion of the population without access to proper healthcare services. In addition, the lack of a sufficient number of influenza test labs is also hindering the market growth of flu diagnostic and treatment in India. Moreover, the increasing number of influenza cases in the country is also projected to bolster the growth of the flu diagnostic and treatment market growth during the forecast period and beyond. For instance, According to the NCDC (National Centre for Disease Control) statistics, the total cases of influenza in India surged from 525 in 2013 to 28,798 in 2019.
The Indian flu and diagnostics market has been segmented on the basis of the type of flu, offering, age group, and end-user. On the basis of the type of flu, the market has been classified on the basis of type A and type B. The type A segment is anticipated to hold a noteworthy share in the flu diagnostic and treatment market in India as this is the most common type of influenza diagnosed in the country. By offering, the market has been segmented into diagnostics and therapeutics. By the age group the market has been segmented on the basis of 0-14 years, 15-64 years and >=65 years. The >=65 age group is projected to hold a notable share during next five years as there is a continuous increase in the geriatric population in India. By the end-user, the segmentation has been done on the basis of hospital laboratory, outpatient clinic, and reference laboratory.
Prominent key market players in India flu diagnostic and treatment market include Abbott, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific and 3M among others. These companies hold a noteworthy share in the market on account of their good brand image and product offerings. Major players in India flu diagnostic and treatment market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.